Viewing Study NCT03819777



Ignite Creation Date: 2024-05-06 @ 12:40 PM
Last Modification Date: 2024-10-26 @ 1:02 PM
Study NCT ID: NCT03819777
Status: UNKNOWN
Last Update Posted: 2021-09-08
First Post: 2018-09-05

Brief Title: Volatile Organic Compounds VOCs as a Biomarker in Immune-mediated Pulmonary Arterial Hypertension PAH
Sponsor: Maastricht University Medical Center
Organization: Maastricht University Medical Center

Study Overview

Official Title: Volatile Organic Compounds as a Biomarker in Immune-mediated Pulmonary Arterial Hypertension
Status: UNKNOWN
Status Verified Date: 2021-08
Last Known Status: RECRUITING
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: VOC-PAH
Brief Summary: Aim to investigate the role of inflammation and auto-immunity in pulmonary arterial hypertension by using the profile of volatile organic compounds

Hypothesis first the investigators hypothesize that at time of diagnosis the VOC profiles will discriminate patients with PAH-CTD and idiopathic PAH IPAH from patients with systemic sclerosis or systemic lupus erythematosus CTD without PAH supporting the contention that there is a overlapping inflammatory and auto-immune pathway in PAH During follow-up the investigators will measure the VOC profiles of patients in all three groups who will be treated according standard clinical care The hypothesis is that VOC profiles are affected by therapy
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None